Document is current
Any future updates will be listed below
-
Authors
De Pascale, Gennaro
Cortegiani, Andrea
Rinaldi, Matteo
Antonelli, Massimo
Cattaneo, Sergio
Cecconi, Maurizio
Cuffaro, Raffaele
Dalfino, Lidia
Di Biase, Filomena
Donati, Abele
Fasano, Francesca Romana
Fasciana, Teresa
Foti, Giuseppe
Frattari, Antonella
Fumagalli, Roberto
Girardis, Massimo
Gottin, Leonardo
Mattei, Alessia
Milazzo, Marta
Montrucchio, Giorgia
Pasero, Daniela
Picciafuochi, Fabio
Sensi, Emanuela
Servillo, Giuseppe
Vidal Pereira, Maria Alejandra
Spanu, Teresa
Viale, Pierluigi
,
Cutuli, Salvatore Lucio
Tanzarella, Eloisa Sofia
Carelli, Simone
Montini, Luca
Giarratano, Antonino
Aceto, Romina
Casari, Erminia
Brazzi, Luca
Curtoni, Antonio
Serio, Lucia
Ferrari, Filippo
Savini, Vincenzo
Taiana, Matteo
Mazzariol, Annarita
Ambretti, Simone
Merola, Grazia
Degl’Innocenti, Linda
Ricciardi, Renato
Gherardi, Giovanni
Guerrero, Fernando Arnaiz
Vismara, Chiara
Vittorielli, Elena
Casarotta, Erika
Vargas, Maria
Rona, Roberto
Cavallero, Annalisa
Muroni, Angela
Rubino, Salvatore
Viaggi, Bruno
Giani, Tommaso
Ippolito, Mariachiara
Tiri, Beatrice
Cappanera, Stefano
Mariottini, Alessandro
Stufano, Monica
Mosca, Adriana
Monti, Giacomo
Buffoli, Fabio
- License Information
-
More Information
Article History
Received: 25 November 2024
Accepted: 8 January 2025
First Online: 17 January 2025
Declarations
:
: Not applicable.
: F.R.F and M.A.V.P. are Pfizer employees. G.D.P. received research grants from Pfizer and Gilead. A.C. received fees for lectures or advisory board membership from Gilead, MSD, Mundipharma, Pfizer. M.A. received fees for board participation from Shionogi, Menarini and Pfizer, and research grant from GE and Fisher & Paykel. A.D. received fees from Aspen, BIOVIIIx, Edwards, Grifols, Viatris. A.F. received fees for scientific communication from Shionogi and Grifols. M.G. received fees for advisory board and speaking service at congresses from Pfizer, Gilead, MSD, Thermofisher. G.M. received fee for board participation form Gilead, 3 M, Thermofisher and was a lecturer for Pfizer. F.P was Co-Principal investigator for the profit study “Clinical and economic evaluation of faster versus conventional AST in Covid-19 and non Covid-19 ICU patients with bloodstream infections (LIFETIMES study)”, sponsored by HEOR-Qlinea. P.V. was a consultant/speaker for Shionogi, an advisor/speaker for Gilead, Pfizer, Merck, Biomerieux, Advan, an advisor for Menarini, and received research grant from Advanz and Gilead. The other authors declare no conflict of interest.
